CELLID, CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,790 KRW | 0.00% |
|
-0.26% | -15.21% |
| 2023 | Cellid, Co., Ltd.(KOSDAQ:A299660) dropped from S&P Global BMI Index | CI |
| 2021 | Private S.Korea firms plan $5.4 billion investment to create vaccine hub | RE |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 480 657K | Sales 2023 | - | Capitalization | 60.81B 83,261B |
|---|---|---|---|---|---|
| Net income 2022 | -22.86B -31,309B | Net income 2023 | -11.61B -15,899B | EV / Sales 2022 | 224,134,002 x |
| Net cash position 2022 | 6.76B 9,253B | Net cash position 2023 | 3.42B 4,681B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5
x | P/E ratio 2023 |
-4.15
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.02% |
More Fundamentals
* Assessed data
More news
| 1 week | -0.26% | ||
| Current month | -0.26% | ||
| 1 month | -9.11% | ||
| 3 months | -11.45% | ||
| Current year | -15.21% |
1 week
3 735.00
3 905.00
1 month
3 730.004 190.00
Current year
3 730.005 560.00
1 year
3 100.009 360.00
3 years
3 100.00156 800.00
5 years
3 100.00156 800.00
10 years
3 100.00156 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chang-Yul Kang
CEO | Chief Executive Officer | 70 | - |
Min-Soo Kim
DFI | Director of Finance/CFO | 50 | - |
BeomSoo Han
BRD | Director/Board Member | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Yul Kang
CEO | Chief Executive Officer | 70 | - |
Yookyung Kim
BRD | Director/Board Member | - | - |
Hyonsoo Kwon
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 3,790 | 0.00% | 19,555 |
| 24-05-07 | 3,790 | -1.17% | 13,000 |
| 24-05-03 | 3,835 | +1.72% | 18,207 |
| 24-05-02 | 3,770 | -0.79% | 22,459 |
| 24-04-30 | 3,800 | +0.26% | 28,519 |
End-of-day quote Korea S.E., May 07, 2024
More quotes
Cellid, Co., Ltd. is a Korea-based company mainly engaged in the research and development of cancer therapeutic vaccine. The Company develops cancer therapeutic vaccine through development and clinical research of BVAC pipeline products using CeliVax original technology.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.21% | 37.77M | |
| +2.93% | 108B | |
| +7.02% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- A299660 Stock